U.S., May 6 -- ClinicalTrials.gov registry received information related to the study (NCT06957808) titled 'Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia' on May 02.
Brief Summary: Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people. It is ranked the third most disabling illness worldwide. Six in seven patients do not recover from the illness in 6-12 months and continue to experience psychotic symptoms. Therefore, there is a strong unmet need for new evidence-based treatments to target the neurobiology underlying schizophrenia. There is increasin...